Sanofi (NASDAQ: SNY) jumped about 5% on October 30, 2026 after the drugmaker raised its full-year guidance for the second time this year on Dupixent strength. The move lifted the shares back above the 200-day average. For the next 2–6 weeks the balance of evidence now leans positive with medium conviction, reversing the negative reading of October 22. The stock is stretched short term, and the price still sits well below the average analyst target.
Why it matters
The third-quarter numbers were strong. Net sales were €14,444m, up 14.3% at constant exchange rates, and Dupixent rose 34.8% to €5.7 billion, according to the company press release. Newer launches grew 31.4% to €1.4 billion, while vaccines fell 6.6% to €3.2 billion on expected phasing. Bloomberg reports that sales growth is now guided to the low teens at constant rates, up from the previous 10%.
The reaction shows how much the market had priced in. Before this print SNY was down about 6.6% for the year and 2.8% over six months, so expectations were low. Pipeline doubts had capped the shares, and a guidance raise forced a repricing. The market did not help: SPY fell 1.21% today as Alphabet's sell-off hit technology, yet SNY rose. Over five days the stock is up 8.8%, against 0.7% for SPY and 1.5% for the healthcare sector ETF XLV. That leaves about 7.3 points of outperformance versus the sector, so the move belongs mostly to the stock and its earnings, not to the market or the sector.
The argument about SNY is no longer about current sales. It is about what replaces Dupixent. The Financial Times notes that Dupixent produced €15.7bn of last year's €43.6bn revenue and loses patent protection in the early 2030s. New CEO Belén Garijo, who replaced Paul Hudson in May, is under pressure to find a successor. Garijo says deals will be critical to the turnaround, and Reuters Breakingviews described the $7 billion Regeneron agreement of October 1 as needing an extra shot of M&A. The positive side is argued in Seeking Alpha, where one analyst says the market overprices pipeline risk. Morningstar also named SNY among its new 5-star stocks in late September. A big acquisition could help or hurt, and today's news does not settle that.
On valuation, nine analysts rate the stock a buy, with a mean price target of $53.61 in a range from $44.00 to $63.00. At $45.28 the shares trade 15.5% below the mean target and only just above the lowest one. Either the spread reflects real disagreement about the pipeline, or the stock still has ground to recover.
What the evidence says
The long-term thesis has moved from broken to repaired, though not fully. On October 22 the reading was bearish with high conviction: price was below its 40-week average, and the level that would have changed that was a weekly close above the 50-day average at $42.46. Price is now above the 40-week average and has reclaimed the 200-day average at $44.33, while the 50-day average sits at $42.22. The stock is early in a recovery phase, not in an established uptrend. It is still 13.5% below its 52-week high of $52.34 and down for the year. The earlier bearish reading no longer fits the evidence, and the earnings print is what changed it.
For the next 2–6 weeks the balance of evidence leans positive, with medium conviction: two of four points. The daily trend runs with the weekly uptrend. SNY leads the S&P 500 over 50 days by 8.3%. It lags XLV over 50 days by 1.4%, which works against the trend and is one reason conviction is not higher.
The strongest case against is that the move is stretched. RSI is 76.5, in overbought territory. After past RSI crossings above 70, the stock was higher a month later 58.7% of the time across 583 cases, below the 61.8% typical for any month, with a median gain of 0.92%. Volume so far today is 30.5% below its 20-day average, though the session is still under way. After reclaiming the 200-day average, the stock was higher a month later 59.3% of the time across 91 cases, with a median gain of 1.69%. Neither history is strong. They suggest a pause is as likely as a run, which is why conviction stops at medium. Still, the trend, the relative strength against the market and a fundamental trigger all point the same way, which keeps the balance positive.
Levels that matter
The structure holds above $45.08, a swing zone just under the current price. A close under it would be the first crack. The trend ends below $44.33, the 200-day average, which the stock reclaimed only today. Below that the recovery would look like a one-day spike. Further support sits at $43.36 and the 50-day average at $42.22.
The breakout level is a daily close above $45.95 on volume above its 20-day average. From there the first target is $48.47, which gives 2.3 to 1, and the second is the 52-week high at $52.34, which gives 5.8 to 1. The stop sits at $44.84, which is $45.08 minus a quarter of the 14-day ATR. The math clears 3 to 1 on the second target, but not the first. Today's light volume means the volume condition has not yet been met.
What would change the picture
A weekly close below $44.33, the 200-day average, would change the picture and put the earlier negative reading back in play. The non-price fact most likely to do it is evidence that Dupixent growth is fading from this quarter's 34.8%, or a pipeline setback that revives the concern the guidance raise has only pushed aside.
What to watch
- Earnings: the third-quarter report came out today, October 30, 2026. The number that matters is Dupixent growth, which was 34.8% this quarter. Vaccines, down 6.6%, are the drag to follow.
- Sector and market: XLV moves the stock before its own news does. It is up 7.8% over a month and 1.76% today. The technology sell-off led by Alphabet is the market risk, and a weaker euro, noted by Bloomberg, helps European exporters like Sanofi.
- Deals: any acquisition announcement, given the CEO's stated focus on business development.
- Valuation: the price is 15.5% under the $53.61 mean target. The stock needs to clear $45.95 before the gap to the target narrows.